重组人促血小板生成素治疗急性白血病化疗后血小板减少症的效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (427 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Recombinant Human Thrombopoietin in the treatment of acute leukemia with thrombocytopenia after chemotherapy.Methods A total of 60 acute leukemia patients with thrombocytopenia after chemotherapy in the Department of Hematologic Lymphoma of the First People′s Hospital of Foshan City from January 2019 to January 2021 were selected as the study subjects,and they were divided into observation group(30 cases) and control group (30 cases) by computer two-color ball grouping method.The patients in the observation group were treated with Recombinant Human Thrombopoietin,and the patients in the control group were treated with Recombinant Human Interleukin-11.The platelet improvement time,platelet levels before and after treatment and adverse drug reactions were compared between the two groups.Results The times of duration of of platelet index below 50×109/L and platelet index recovery to 70×109/L in the observation group were shorter than those in the control group,and the differences were statistically significant (P<0.05).The level of platelet in the two groups after treatment were higher than those before treatment,the differences were statistically significant (P<0.05).The level of platelet in observation group was higher than that in the control group after treatment,the difference was statistically significant (P<0.05).The total incidence of adverse drug reactions in observation group was lower than that in control group,the difference was statistically significant (P<0.05).Conclusion Recombinant Human Thrombopoietin is effective and safe in the treatment of acute leukemia with thrombocytopenia after chemotherapy.

Key words： Recombinant Human Thrombopoietin Acute leukemia Chemotherapy Thrombocytopenia

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	QI Yonglei
	ZHAO Ying

Cite this article:

QI Yonglei,ZHAO Ying. Effect of Recombinant Human Thrombocytopenia in the treatment of acute leukemia with thrombocytopenia after chemotherapy[J]. 中国当代医药, 2022, 29(14): 90-92.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I14/90

[1]	陈凤华，姜华，李亚娟.重组人促血小板生成素治疗急性白血病化疗后血小板减少症的疗效[J].中国医药指南，2019，17（33）：162-163.
[2]	刘方媛，郭建民，刘缦缦，等.重组人血小板生成素治疗老年急性髓系白血病化疗后血小板减少的效果观察[J].中国实用医刊，2019，46（9）：96-98.
[3]	赵水平，靳洁.急性白血病化疗后血小板减少症应用rhTPO的效果[J].深圳中西医结合杂志，2019，29（1）：179-180.
[4]	中国临床肿瘤学会（CSCO）抗白血病联盟，中国临床肿瘤学会（CSCO）抗淋巴瘤联盟.急性白血病化疗所致血小板减少症诊疗中国专家共识[J].白血病·淋巴瘤，2019，28（4）：193-197.
[5]	王少怡，余自强.血小板生成素受体激动剂的研究现状及临床应用[J].国际输血及血液学杂志，2020，43（2）：122-128.
[6]	杨丽华.急性白血病化疗后血小板减少症应用重组人促血小板生成素治疗的效果分析[J].医药前沿，2018，8（24）：198.
[7]	赵水平.重组人促血小板生成素对化疗后血小板减少症的临床疗效[J].实用中西医结合临床，2018，18（1）：105-106.
[8]	王战芳，张芳芳，王敏芳.减低剂量人免疫球蛋白联合重组人促血小板生成素、糖皮质激素治疗原发免疫性血小板减少症临床观察[J].药品评价，2020，17（8）：62-64.
[9]	蒋媛，史桂玲，张惠娟，等.1 例低分子肝素钙诱导血小板减少症的药学监护[J].医药导报，2017，36（4）：406-409.
[10]	张培蕾，周耕，程永德.肝素诱导性血小板减少症相关研究进展[J].介入放射学杂志，2017，26（5）：385-389.
[11]	弓小雪，刘俊丽，党瑞丽，等.2 例肝素诱导性血小板减少症患者的药学监护[J].医药导报，2017，36（12）：1426-1428.
[12]	覃薇，黄少玲，李婷婷.抗-D 免疫球蛋白治疗儿童免疫性血小板减少症疗效的Meta 分析[J].中国当代儿科杂志，2017，19（10）：1070-1076.
[13]	卢晓南，伍庆华，尚广彬，等.化疗致血小板减少症治疗的研究进展[J].中国中医药现代远程教育，2017，15（18）：149-152.
[14]	吴晓勇，陈广雷，王云龙，等.T 细胞与免疫性血小板减少症发病机制的相关性研究进展[J].山东医药，2017，57（4）：101-104.
[15]	李玲，周瑜，李洁.重组人促血小板生成素治疗实体瘤化疗所致血小板减少的效果观察[J].当代医学，2019，25（36）：129-131.
[16]	张荣侠.重组人促血小板生成素与白介素-11 治疗恶性肿瘤化疗后血小板减少症的疗效评价[J].临床医药文献电子杂志，2019，6（84）：180-181.
[17]	杜以萍，张充力，毕珍宁.糖皮质激素联合重组人促血小板生成素治疗特发性血小板减少性紫癜[J].血栓与止血学，2014，20（2）：79-80.
[18]	章亚威，倪亚茹，徐晓军，等.重组人促血小板生成素对白血病化疗后血小板减少症的疗效研究[J].血栓与止血学，2020，26（4）：558-560.